Three VPC publications describe potential new therapeutics

Date Posted: 
2017-09-13

Thee publications out of the VPC describing work towards the development of new therapeutics were published in the last week.

A study led by Drs. Michael Cox, Artem Cherkasov, and Paul Rennie is featured in a Sept. 6th news story from the Terry Fox Research Institute. Published in Oncotarget, the work describes a first-in-class small molecule targeting the DNA binding domain of the ETS-family transcription factor, ERG. The study shows that that disrupting ERG transcriptional activity is sufficient to suppress the major characteristics of ERG-transformed prostate cancers; this finding could help develop new therapeutic tools for men battling ERG-expressing metastatic castration-resistant prostate cancer.

A study led by Dr. Gleave is featured in a Sept. 11th Publications of the Week post by Science in the City.  The European Urology publication describes the evaluation of the novel drug darolutamide in preclinical models of prostate cancer and found that darolutamide delays growth of enzalutamide-resistant prostate cancer, in particular in cells with mutated forms of the androgen receptor after previous treatment. This data supports further evaluation of darolutamide in clinical trials.

A study lead by Dr. Zoubeidi was published on Sept. 12 in Clinical Cancer Research online. In this preclinical study, the group investigated molecular targets and therapeutics for PCS1, the most aggressive and lethal subtype of prostate cancer. They report that the Forkhead box M1 (FOXM1) pathway is the central driver of this subtype in enzalutamide castration-resistant prostate cancer, and targeting FOXM1 reduces cell growth and stemness. These preclinical results may guide clinical evaluation of targeting FOXM1 to eradicate highly aggressive and lethal PCS1 prostate cancer tumours.

A World Class Centre

The Vancouver Prostate Centre (VPC) has a track record of success that has earned it a reputation as one of the world’s most respected cancer facilities. It is a National Centre of Excellence and a designated Centre of Excellence for Commercialization and Research.

Events

Pars for Prostate fundraiser: September 22, 2022

The First Annual Pars for Prostate golf fundraiser in support of Prostate Cancer Foundation BC takes place September 22, 2022 at Westwood Plateau Golf Course. For information and to register please visit www.parsforprostate.ca

Dr. Black

Terry Fox Run fundraiser: September 18th, 2022

The 42nd Annual Terry Fox Run is taking place on Sunday September 18, 2022. If you are able, please consider joining and/or donating to our team (tax receipts issued), raising funds for the Terry Fox Foundation's ground-breaking cancer research

Employment

Work at the Vancouver Prostate Centre

Wednesday, July 20, 2022

With just a tablespoon of blood, B.C. researchers aim to transform cancer treatment

Wednesday, July 13, 2022

Dr. Govind Kaigala appointed Senior Research Scientist

Dr. Govind Kaigala